BRAF L597 mutations in melanoma are associated with sensitivity to MEK inhibitors

Kinase inhibitors are accepted treatment for metastatic melanomas that harbor specific driver mutations in BRAF or KIT, but only 40–50% of cases are positive. To uncover other potential targetable mutations, we performed whole-genome sequencing of a highly aggressive BRAF (V600) and KIT (W557, V559,...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Dahlman, Kimberly Brown, Xia, Junfeng, Hutchinson, Katherine, Ng, Charles, Hucks, Donald, Jia, Peilin, Atefi, Mohammad, Su, Zengliu, Branch, Suzanne, Lyle, Pamela L., Hicks, Donna J., Bozon, Viviana, Glaspy, John A., Rosen, Neal, Solit, David B., Netterville, James L., Vnencak-Jones, Cindy L., Sosman, Jeffrey A., Ribas, Antoni, Zhao, Zhongming, Pao, William
Formato: Artigo
Idioma:Inglês
Publicado em: 2012
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3449158/
https://ncbi.nlm.nih.gov/pubmed/22798288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/2159-8290.CD-12-0097
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados